Abstract
Introduction
New approaches in vaccines, such as DNA vaccines, new combination vaccines,
new formulations, novel delivery routes, new adjuvants are being explored. In
the last three years the cancer vaccine industry has reshaped itself quite
considerably. The number of cancer vaccine players has rather decreased than
increased, through operational re-prioritizations, M&As and fall outs.
Scope of this report
- In-depth competitive landscape assessment of the cancer vaccine market
- Tumor antigen discovery and technologies surrounding it
- Thorough review of immunomodulating strategies and adjuvants
- Thorough review of cancer vaccine delivery and technologies surrounding it
- Progress analysis of six major cancer vaccine indications, including
players, drugs, clinical progress and pitfalls
Research and analysis highlights
Research and development in the cancer vaccine field is dominated by its top
10 players, interestingly not including any of the big pharma companies per
se. The recent Gardasil approval and GlaxoSmithKline's acquisition of Corixa
will certainly push the industry towards more acquisitions. With this in mind,
this report makes an in-depth assessment of competitive landscape, tumor
antigen technologies, immunostimulatory strategies, vaccine delivery
technologies, and a progress analysis of six major cancer vaccine indications.
View Cart
